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ABSTRACT
Objective Cervical length screening by transvaginal
sonography (TVS) has been shown to be a good predictive
test for spontaneous preterm birth (PTB) in symptomatic
singleton pregnancy with threatened preterm labor
(PTL). The aim of this review and meta-analysis of
individual participant data was to evaluate the effect
of knowledge of the TVS cervical length (CL) in
preventing PTB in singleton pregnancies presenting with
threatened PTL.
Methods We searched the Cochrane Pregnancy and
Childbirth Group’s Trials Register and the Cochrane
Complementary Medicine Field’s Trials Register (May
2016) and reference lists of retrieved studies. Selection
criteria included randomized controlled trials of sin-
gleton gestations with threatened PTL randomized to
management based mainly on CL screening (interven-
tion group), or CL screening with no knowledge of
results or no CL screening (control group). Participants
included women with singleton gestations at 23 + 0 to
36 + 6 weeks with threatened PTL. We contacted cor-
responding authors of included trials to request access
to the data and perform a meta-analysis of individ-
ual participant data. Data provided by the investiga-
tors were merged into a master database constructed
specifically for the review. The primary outcome was
PTB < 37 weeks. Summary measures were reported as
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relative risk (RR) or as mean difference (MD) with
95% CI.
Results Three trials including a total of 287 singleton ges-
tations with threatened PTL between 24 + 0 and 35 + 6
weeks were included in the meta-analysis, of which 145
were randomized to CL screening with knowledge of
results and 142 to no knowledge of CL. Compared
with the control group, women who were randomized
to the known CL group had a significantly lower rate of
PTB < 37 weeks (22.1% vs 34.5%; RR, 0.64 (95% CI,
0.44–0.94); three trials; 287 participants) and a later ges-
tational age at delivery (MD, 0.64 (95% CI, 0.03–1.25)
weeks; MD, 4.48 (95% CI, 1.18–8.98) days; three trials;
287 participants). All other outcomes for which there
were available data were similar in the two groups.
Conclusions There is a significant association between
knowledge of TVS CL and lower incidence of PTB
and later gestational age at delivery in symptomatic
singleton gestations with threatened PTL. Given that in
the meta-analysis we found a significant 36% reduction
in the primary outcome, but other outcomes were mostly
statistically similar, further study needs to be undertaken
to understand better whether the predictive characteristics
of CL screening by TVS can be translated into better
clinical management and therefore better outcomes and
under what circumstances. Copyright © 2016 ISUOG.
Published by John Wiley & Sons Ltd.
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INTRODUCTION
Spontaneous preterm birth (PTB) remains the main cause
of perinatal morbidity and mortality in many countries,
including the USA1. Mortality and morbidities, including
respiratory distress syndrome (RDS), intraventricular
hemorrhage (IVH), necrotizing enterocolitis (NEC) and
sepsis, are inversely associated with gestational age at
birth1,2.
Cervical length (CL) measured by transvaginal sono-
graphy (TVS) has been shown to be an effective predictor
of spontaneous PTB3,4. This finding has been confirmed
in singleton and multiple gestations, in women with or
without risk factors for PTB, and in asymptomatic women
as well as women with preterm labor (PTL) or preterm
prelabor rupture of membranes (PPROM)4. One of the
challenges in the management of women who present with
PTL is the distinction between true and false PTL. Women
with threatened PTL are usually managed according to
cervical dilation detected on digital (manual) vaginal
examination. However, most women with threatened
PTL have minimal cervical dilation (≤ 2 cm) on manual
examination and about 75% do not deliver preterm3,4.
Therefore, in these women, CL on TVS has been suggested
as a better screening tool to determine the need for
intervention4. It has been hypothesized that management
of PTL patients with CL measurement leads to treatment
of women truly at risk for PTB, and avoids intervention
in women not at risk (e.g. those with CL ≥ 30 mm)4.
It remains controversial whether management of these
women based on TVS CL results would decrease the
incidence of PTB. The aim of this systematic review and
meta-analysis of randomized clinical trials (RCTs) was
to evaluate the effectiveness of management of singleton
pregnancies with threatened PTL based on knowledge of
the CL measurement compared with no knowledge of CL.
METHODS
Search strategy
This meta-analysis was performed according to a
protocol recommended for systematic reviews5. The
review protocol was designed a priori, defining methods
for collecting, extracting and analyzing data. We searched
the Trials Register of the Cochrane Pregnancy and
Childbirth Group (PCG) by contacting the PCG Trials
Search Co-ordinator.
Briefly, the Cochrane PCG Trials Register is maintained
by the Trials Search Co-ordinator and contains trials
identified from (1) monthly searches of the Cochrane
Central Register of Controlled Trials (CENTRAL); (2)
weekly searches of MEDLINE (Ovid); (3) weekly searches
of EMBASE (Ovid); (4) monthly searches of CINAHL
(EBSCO); (5) hand-searching of 30 journals and the
proceedings of major conferences; and (6) weekly current
awareness alerts for a further 44 journals plus monthly
BioMed Central email alerts. The search was conducted
from the inception of each database to May 2016. Search
results were screened by two people and the full text of
all relevant trial reports identified through the searching
activities described above was reviewed. Based on the
intervention described, each trial report was assigned a
number that corresponded to a specific PCG review topic
(or topics), and was then added to the Register. The
Trials Search Co-ordinator searched the Register for each
review using this topic number rather than keywords.
This resulted in a more specific search set that was fully
accounted for in the relevant review sections (Included,
Excluded, Awaiting Classification or Ongoing).
In addition, we contacted the Cochrane Complemen-
tary Medicine Field to search their Trials Register and
checked again via The Cochrane Register of Studies
(CRSO).
Study selection
Selection criteria included RCTs of singleton gestations
with threatened PTL randomized to management based
on TVS CL screening results (intervention group) or
not (control group). Participants included women with
singleton gestation at 23 + 0 to 36 + 6 weeks with
threatened PTL. For this review, TVS CL screening
modalities on which interventions were based were either
(1) knowledge vs no knowledge of CL, i.e. CL was
measured in all women, but they were randomized so that
the results were available to the managing obstetrician
only in the intervention group (known CL group), and
the managing obstetrician was blinded to the CL results
in the control group (no knowledge of CL); or (2) TVS CL
vs no TVS CL measurement, i.e. women were randomized
to TVS CL screening or no TVS CL screening.
Studies that included management based only on fetal
fibronectin (FFN) were excluded. Quasirandomized trials
(i.e. trials in which allocation was done on the basis
of a pseudorandom sequence, e.g. odd/even hospital
number or date of birth, alternation), studies on multiple
pregnancies and studies on PPROM were also excluded.
Data extraction and risk of bias assessment
The risk of bias in each included study was assessed
using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions5. Seven domains
related to risk of bias were assessed in each included trial
since there is evidence that these issues are associated with
biased estimates of treatment effect: (1) random sequence
generation; (2) allocation concealment; (3) blinding of
participants and personnel; (4) blinding of outcome
assessment; (5) incomplete outcome data; (6) selective
reporting; and (7) other bias. Review authors’ judgments
were categorized as ‘low risk’, ‘high risk’ or ‘unclear risk’
of bias5.
For this review, the quality of the evidence was assessed
using the GRADE approach in order to assess the quality
of the body of evidence relating to the primary and the
main seven secondary outcomes in the overall analysis.
The GRADEpro Guideline Development Tool was used
Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2017; 49: 322–329.
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to import data from Review Manager 5.3 (The Nordic
Cochrane Centre, Cochrane Collaboration, Copenhagen,
Denmark, 2014) in order to create a ‘Summary of findings’
table. A summary of the intervention effect and a measure
of quality for each of the above outcomes was produced
using the GRADE approach. This uses five considerations
(study limitations, consistency of effect, imprecision,
indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence
can be downgraded from ‘high quality’ by one level for
serious (or by two levels for very serious) limitations,
depending on assessments for risk of bias, indirectness
of evidence, serious inconsistency, imprecision of effect
estimates or potential publication bias5.
All analyses were done using an intention-to-treat
approach, evaluating women according to the treatment
group to which they were allocated randomly in the
original trials. Primary and secondary outcomes were
planned a priori. The primary outcome was the incidence
of PTB< 37 weeks. Secondary outcomes were PTB< 36,
< 34, < 32, < 30 and< 28 weeks, gestational age at deliv-
ery, latency (time from randomization to delivery), time
from evaluation to discharge, low birth weight (< 2500 g),
composite perinatal outcome (defined as at least one of
the following: perinatal death, RDS, IVH and sepsis), fetal
death (fetal death after 20 weeks), neonatal death (death of
a live-born baby within the first 28 days of delivery), peri-
natal death (fetal death and neonatal death), RDS, IVH,
NEC, sepsis, admission to the neonatal intensive care unit
(NICU), days in NICU, maternal hospitalization for more
than 24 h, maternal wellbeing (stress level), economic ana-
lysis (cost-effectiveness, cost-utility), tocolysis, cervical
cerclage, steroids for fetal maturity, chorioamnionitis
and endometritis. We contacted corresponding authors
of all included trials to request access to the data and
perform a meta-analysis of individual participant data
(IPD). Authors were asked to supply anonymized data
(without identifiers) about patient baseline character-
istics, experimental intervention, control intervention,
co-interventions, and prespecified outcome measures for
every randomly assigned subject and were invited to
become part of the collaborative group with joint author-
ship of the final publication. Data provided by the
investigators were merged into a master database con-
structed specifically for the review. Data were checked
for missing information, errors and inconsistencies by
cross-referencing the publications of the original trials.
Quality and integrity of the randomization processes were
assessed by reviewing the chronological randomization
sequence and pattern of assignment, as well as the balance
of baseline characteristics across treatment groups. Incon-
sistencies or missing data were discussed with the authors
and corrections were made when deemed necessary.
Statistical analysis
Data analysis was completed independently by two
authors (V.B., G.S.) using Review Manager 5.35. The
Records identified through
database search
(n = 22)
Records after duplicates
removed
(n = 20)
Records screened
(n = 20)
Records excluded
(not randomized trial)
(n = 7)
Full-text articles excluded (n = 10):
 •   Studies on FFN (n = 8)
 •   Studies on twins (n = 1)
 •   Studies on PPROM (n = 1)
Full-text articles assessed
for eligibility
(n = 13)
Studies included in
qualitative synthesis
(n = 3)
Studies included in
quantitative synthesis
(meta-analysis)
(n = 3)
Figure 1 Flowchart of randomized controlled trials identified for
systematic review. FFN, fetal fibronectin; PPROM, preterm
prelabor rupture of membranes.
completed analyses were then compared and any differ-
ence was resolved with review of the entire data and inde-
pendent analysis. IPD were analyzed using the so-called
two-stage approach5. In this, the IPD are first analyzed
separately in each study to produce study-specific esti-
mates of relative treatment effect. A combined estimate is
then obtained in the second step by calculating a weighted
average (inverse error variance based) of the individ-
ual estimates using methods analogous to meta-analyses
of aggregate data. Between-study heterogeneity was
explored using the I2 statistic, which represents the
percentage of between-study variation that is due to
heterogeneity rather than chance. Meta-analysis was per-
formed using the random-effects model of DerSimonian
and Laird, to produce summary treatment effects in terms
of either a RR or a mean difference (MD) with 95% CI.
We planned to assess the primary outcomes in subsets
of women with prior spontaneous PTB and according to
the gestational age at randomization.
Potential publication biases were assessed statistically
using Begg’s and Egger’s tests. P< 0.1 was considered
statistically significant.
Characteristics of the included women obtained in the
merged database were analyzed using SPSS Statistics v.
19.0 (IBM Inc., Armonk, NY, USA). Data are shown
as mean ± SD or as n (%). Univariate comparisons of
dichotomous data were performed by the chi-square
or Fisher’s exact test. Comparisons between groups
were performed with the use of Student’s t-test to test
group means with SD. Two-sided P-values< 0.05 were
considered statistically significant.
Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2017; 49: 322–329.
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Figure 2 Risk of bias following The Cochrane Handbook5 in
individual randomized controlled trials (RCTs) (a) and across
RCTs (b) included in meta-analysis. Only first author of each study
is given. Risk of bias: , +, low; , ?, unclear ; , −, high.
All review stages were conducted independently by
two reviewers (V.B., G.S.). The two authors assessed
independently the electronic search, eligibility of the
studies, inclusion criteria, risk of bias, data extraction and
data analysis. Disagreements were resolved by discussion.
The meta-analysis was reported following the Preferred
Reporting Item for Systematic Reviews and Meta-analyses
(PRISMA) IPD statement6. Before data extraction, the
review was registered with the Cochrane Database
of Systematic Reviews (review no. 0133) and with
the PROSPERO International Prospective Register of
Systematic Reviews (registration no. CRD42016042023).
RESULTS
Study selection and characteristics
From a total of 22 records identified through database
searching, three trials7–9 including a total of 287 singleton
gestations with threatened PTL, of which 145 were
randomized to knowledge of CL and 142 to no knowledge
of CL, were included in the meta-analysis (Figure 1).
Ness et al.8 used mainly knowledge of TVS CL in the
management protocol; however, for women with a CL of
20–29 mm, results of FFN assessment were also used.
The overall risk of bias of the included trials was
low (Figure 2). All studies had a low risk of bias in T
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Table 2 Summary of management protocols in randomized controlled trials comparing effectiveness of knowledge of cervical length (CL)
with no knowledge of CL (controls) in preventing preterm birth
Study
CL cut-off
used for
management
Management of
known CL group
Incidence of short
CL*(n/N (%)) Control group
Management of
controls
Palacio (2006)9 <25 mm If positive (short CL),
further observation; if
negative, early discharge
within 12 h
<25 mm: 22/75 (29.3) vs
20/74 (27.0)
CL measured but
managing physicians
blinded to result
Physician’s discretion
Alfirevic (2007)7 <15 mm If positive (short CL),
tocolytics and antenatal
corticosteroids; if
negative, further
observation and early
discharge†
<15 mm: 7/21 (33.3) vs
not measured in control
group
CL not measured Tocolytics and
antenatal
corticosteroids
Ness (2007)8 <20 mm‡ If positive (short CL),
tocolytics and antenatal
corticosteroids; if
negative, early discharge
<20 mm: 11/49 (22.4) vs
7/48 (14.6)
CL measured but
managing physicians
blinded to result
Physician’s discretion
Only first author given for each study. *Intervention group with knowledge of CL vs control group with no knowledge of CL. †If uterine
contractions persisted another transvaginal scan was performed 4 h later. ‡If CL was 20–29 mm, fetal fibronectin (FFN) was assessed; if
FFN was negative (< 50 ng/mL) woman was discharged; if FFN was positive woman received tocolytics and antenatal steroids.
Table 3 Characteristics of women with singleton pregnancy and
threatened preterm labor (PTL) in randomized controlled trials
comparing effectiveness of knowledge of cervical length (CL) with
no knowledge of CL (controls) in preventing preterm birth (PTB)
Characteristic
Known CL group
(n = 145)
Controls
(n = 142) P
Race 0.73
African American 37/70 (52.9) 50/68 (73.5)
Non-Hispanic white 27/70 (38.6) 13/68 (19.1)
Hispanic 6/70 (8.6) 5/68 (7.4)
BMI (kg/m2) 24.7 ± 4.82 25.2 ± 3.77 0.73
Smoker 11/70 (15.7) 9/68 (13.2) 0.68
Prior PTB 24/145 (16.6) 22/142 (15.5) 0.80
Primigravid 44/145 (30.3) 47/142 (33.1) 0.61
GA at presentation
with PTL (weeks)
31.4 ± 7.4 31.7 ± 6.4 0.71
Data are given as n/N (%) or mean ± SD. Some data are missing as
not all variables were registered in every database. BMI, body mass
index; GA, gestational age.
random sequence generation and incomplete outcome
data. Adequate methods for allocation of women were
used in all studies. All randomized women were included
in an intention-to-treat analysis. Publication bias, assessed
using Begg’s and Egger’s tests, showed no significant bias
(P = 0.69 and 0.78, respectively). Authors of all three
original trials provided the entire database from their
study in order to obtain additional and unpublished data
and perform IPD meta-analysis.
Table 1 shows the characteristics of the three included
trials. Only singleton gestations with threatened PTL
and without PPROM, between 24 + 0 and 35 + 6 weeks,
were analyzed. Women in the known CL group were
discharged if they had a negative TVS CL screening result
(equal to or longer than 15, 20 or 25 mm, dependent
on the study) or were treated with hospital admission,
tocolytics and antenatal corticosteroids if TVS CL screen-
ing was positive (shorter than 15, 20 or 25 mm, dependent
on the study) (Table 2). In one study9, CL was not used to
decide on admission but rather to help in the decision of
possible early discharge. Women in the control group (no
knowledge of CL) were treated at the physician’s discre-
tion in two studies8,9 and were treated with tocolytics and
antenatal corticosteroids in one study7. Characteristics of
the included women are shown in Table 3.
The method of CL ascertainment was defined clearly
in all studies. Endocervical canal length was measured
as the distance between the internal and external ora
using a vaginal probe placed in the anterior fornix
of the vagina. Three anatomical landmarks defined the
appropriate sagittal view: the internal os, the external
os and the endocervical canal. The image was enlarged
while visualizing the three landmarks simultaneously.
Gentle pressure exerted on the cervix by the transducer
was reduced followed by minimal pressure to allow
visualization of the three landmarks. In all studies, this
procedure was repeated three times and the shortest
measurement was recorded. In all trials, the woman had
an empty bladder during the ultrasound scan.
Synthesis of results
The pooled results for the primary and secondary
outcomes are shown in Table 4. Statistical heterogeneity
was low with no inconsistency in the primary outcome
and secondary outcomes. The methodological quality
of the included studies was mixed. For the primary and
seven main secondary outcomes, we graded the quality
of the evidence as low according to the GRADE criteria.
Compared with the control group, women who were ran-
domized to the known CL group had a significantly lower
rate of PTB<37 weeks (22.1% vs 34.5%; RR, 0.64 (95%
CI, 0.44–0.94); three trials; 287 participants; Figure 3)
and later gestational age at delivery (MD, 0.64 (95% CI,
0.03–1.25) weeks; MD, 4.48 (95% CI, 1.18–8.98) days;
Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2017; 49: 322–329.
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Table 4 Primary and secondary outcomes in randomized controlled trials comparing effectiveness of knowledge of cervical length (CL) with
no knowledge of CL (controls) in preventing preterm birth (PTB)
Outcome
Trials
(nrefs)
Known
CL group Controls
I2
(%) RR or MD*(95% CI)
All singleton pregnancies with thrPTL (n = 287)
PTB< 37 weeks 37–9 32/145 (22.1) 49/142 (34.5) 37 0.64 (0.44 to 0.94)†
PTB< 36 weeks 37–9 28/145 (19.3) 41/142 (28.9) 46 0.67 (0.44 to 1.02)
PTB< 34 weeks 37–9 9/145 (6.2) 16/142 (11.3) 0 0.55 (0.25 to 1.20)
PTB< 32 weeks 37–9 4/145 (2.8) 8/142 (5.6) 0 0.49 (0.15 to 1.59)
PTB< 30 weeks 37–9 1/145 (0.7) 3/142 (2.1) 0 0.49 (0.09 to 2.61)
PTB< 28 weeks 37–9 1/145 (0.7) 0/142 (0) NA 2.96 (0.12 to 71.52)
GA at delivery (weeks) 37–9 37.9 37.3 0 0.64 (0.03 to 1.25)*†
GA at delivery (days) 37–9 266.5 261.3 0 4.48 (1.18 to 8.98)*†
Latency‡ (days) 37–9 52.1 47.6 0 4.41 (–0.33 to 9.44)*
Delivery within 7 days after randomization 37–9 3/145 (2.1) 6/142 (4.2) 0 0.48 (0.12 to 1.95)
Delivery within 14 days after randomization 37–9 10/145 (6.9) 19/142 (13.4) 0 0.48 (0.21 to 1.07)
Time from evaluation to discharge (h) 18 2.17 2.32 NA 0.16 (–0.44 to 7.42)*
Low birth weight 27,8 8/70 (11.4) 9/68 (13.2) NA 0.86 (0.36 to 2.08)
Perinatal death 27,8 0/70 (0) 0/68 (0) NA NA
Length of stay in NICU (days) 27,8 15.3 17.1 0 −1.80 (–5.18 to 1.58)*
Maternal hospitalization 27,8 25/70 (35.7) 17/68 (25.0) 69 1.57 (0.51 to 4.82)
Tocolysis 27,8 16/70 (22.9) 22/68 (32.4) 91 1.14 (0.08 to 16.80)
Steroids for fetal maturity 27,8 27/70 (38.6) 22/68 (32.4) 92 1.83 (0.13 to 26.36)
Singleton pregnancies with prior sPTB (n = 46)
PTB< 37 weeks 37–9 7/24 (29.2) 6/22 (27.3) 0 1.02 (0.43 to 2.41)
Singleton pregnancies with thrPTL< 30 weeks (n = 66)
PTB< 37 weeks 37–9 9/35 (25.7) 12/31 (38.7) 0 0.59 (0.21 to 0.98)†
Singleton pregnancies with thrPTL ≥ 30 weeks (n = 221)
PTB< 37 weeks 37–9 23/110 (20.9) 37/111 (33.3) 0 0.61 (0.32 to 0.97)†
Data are presented as n/N (%) or mean. Some data are missing as not all variables were registered in every database. *Mean difference
(MD). †Statistically significant. ‡Time from randomization to delivery. GA, gestational age; NA, not applicable; NICU, neonatal intensive
care unit; PTL, preterm labor; refs, references; RR, relative risk; sPTB, spontaneous preterm birth; thrPTL, threatened preterm labor.
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Figure 3 Forest plot for risk of preterm birth< 37 weeks in women with singleton pregnancy and threatened preterm labor randomized to
cervical length (CL) screening with knowledge of results (known CL group) or to no knowledge of CL (controls). Only first author is given
for each study. M–H, Mantel–Haenszel.
three trials; 287 participants). All other outcomes for
which there were available data were similar in the two
groups. No data were available regarding the following
prespecified outcomes: composite perinatal outcome, fetal
death, neonatal death, RDS, IVH, NEC, sepsis, admission
to NICU, maternal wellbeing, economic analysis, cervical
cerclage, chorioamnionitis and endometritis.
Subgroup analysis showed no difference in the incidence
of PTB<37 weeks with knowledge of CL in women
with prior spontaneous PTB (29.2% vs 27.3%; RR,
1.02 (95% CI, 0.43–2.41); three trials; 46 participants;
Table 4; Figure 4). However, we found significantly lower
rates of PTB< 37 weeks in the known CL group in
the subgroup of women with threatened PTL<30 weeks
(25.7% vs 38.7%; RR, 0.59 (95% CI, 0.21–0.98); three
trials; 66 participants; Table 4) and ≥ 30 weeks (20.9% vs
33.3%; RR, 0.61 (95% CI, 0.32–0.97); three trials; 221
participants; Table 4).
Quality of evidence
For the comparison of intervention group vs control
group, the quality of evidence was downgraded because
of serious imprecision. Outcomes were imprecise because
studies included relatively few patients and few events and
thus had wide CIs around the estimate of the effect and
because the optimal information size was not reached.
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The quality of the evidence was also downgraded another
level because of serious indirectness due to the different
interventions (Table S1).
DISCUSSION
Main findings
This IPD meta-analysis of three RCTs at low risk of bias,
including 287 women, showed that TVS CL screening
in singleton gestations with threatened PTL between 24
and 35 weeks reduced the rate of PTB and resulted in a
later gestational age at delivery. No other outcomes were
different. However, the quality level of summary estimates
was low, as assessed by GRADE, indicating that the true
effect may, or is even likely to, be substantially different
from the estimate of the effect.
Comparison with previous studies
Our data, which included Level-1 data from well-designed
trials, did not support earlier findings of a Cochrane
review of five trials4. That review, which included also
women with PPROM and multiple gestations, concluded
that there was insufficient evidence to recommend routine
screening of TVS CL in asymptomatic or symptomatic
pregnant women4. Recently, a meta-analysis of six RCTs,
including 546 singleton gestations with symptoms of
PTL, showed that FFN testing alone in women with
threatened PTL was not associated with prevention of
spontaneous PTB or improvement in perinatal outcome
but was associated with higher costs10. As four of the six
RCTs included did not use a standardized management
protocol based on the FFN results, more research may be
needed in the use of FFN alone if TVS CL is unavailable.
Strengths and limitations
An IPD has several distinct advantages over aggregate
data meta-analysis (ADMA). IPD involves the synthesis
of individual-level data from the individual trials,
and therefore allows for the verification of published
results. As IPD are available, an IPD meta-analysis
allows for more flexibility regarding the inclusion and
exclusion of individuals, and the choice of endpoints
and subgroups, compared with ADMA. Furthermore,
IPD from unpublished studies can be included in the
analysis. Other strengths of the study are that this is the
largest meta-analysis so far conducted on the topic and
it includes all currently published RCTs. Moreover, our
study is strengthened by the low influence of publication
bias. Notably, given the low number of included studies,
we were not able to construct reliably funnel plots and the
Begg’s and Egger’s tests have low power. Instead, studies
were identified through trial registries, from which we
were able to identify continuing, as well as terminated
and unpublished, studies.
Many of the limitations of our study are those inherent
to the RCTs included. Only three trials were included in
the meta-analysis. One trial has been published only as
an abstract9. The small number of studies and the small
number of included women did not permit meaningful
stratified meta-analyses to explore the test performance
in subgroups of patients that may be less or more
susceptible to bias. The TVS CL cut-off for intervention
was different among the three trials,< 15 mm7,< 20 mm8
and< 25 mm9. As management of the included women
was based on the TVS CL cut-offs used in the original
trials, analyses to explore the effect of using different
CL cut-offs in the different datasets are not feasible even
with an IPD. Importantly, in one study, TVS CL was
not used to decide on whether to admit the patient, but
rather to help in the decision of possible early discharge9.
The lack of neonatal outcome data limits the conclusions
that can be drawn from this meta-analysis. The only
data available were the duration of stay in NICU, which
did not differ between the groups. The small number
of included trials, different primary outcomes of the
original trials and different definitions for PTL represent
the major limitations of this systematic review. The lack
of definition for threatened PTL in one trial7 and the
lack of uniformity in the definition for PTL among the
trials was the major shortcoming of the meta-analysis.
Defined criteria for NICU admission were lacking. Our
meta-analysis was probably underpowered to detect sig-
nificant decreases in PTB at cut-offs other than 37 weeks,
but trends at 36 weeks (RR, 0.67), 34 weeks (RR, 0.55),
Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2017; 49: 322–329.
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32 weeks (RR, 0.49) and 30 weeks (RR, 0.49) all showed
about a 50% decrease in PTB (Table 4). Finally, the
study was also underpowered to detect differences in the
number and duration of maternal admissions and costs.
Conclusions
In summary, based on these Level-1 data, at least
as used so far in these trials, there is a significant
association between the knowledge of CL and a lower
incidence of PTB< 37 weeks and later gestational age
at delivery in symptomatic singleton gestations with
threatened PTL. Of the three included trials, the one
that was, by itself, associated with a significant decrease
in PTB< 37 weeks used a management protocol that
recommended intervention (admission, tocolysis and
steroids) for women with TVS CL< 20 mm and for
those with a CL of 20–29 mm and a positive FFN
test, and recommended discharge for those with a TVS
CL ≥ 30 mm8. Therefore, we suggest the use of this
management protocol for women with threatened PTL
between 23 + 7 and 33 + 6 weeks8–11.
Our meta-analysis also included women randomized
between 34 + 0 and 35 + 6 weeks. A recent meta-analysis
of six trials, including 5698 singleton pregnancies,
showed that antenatal steroids at ≥ 34 weeks reduce
neonatal respiratory morbidity, and that a single course
of corticosteroids can be considered for women at risk of
imminent late PTB12.
The biological plausibility of our findings is not
completely clear. The benefit may come from better use
of interventions (e.g. admission, tocolysis, steroids) aimed
at women with true PTL, i.e. those with a CL< 20 mm
or 20–29 mm with positive FFN. The other possible
benefit is to avoid unnecessary intervention in women
with threatened PTL who have a reassuring TVS CL. For
example, in the RCT by Ness et al.8, more than 50%
of women had a TVS CL ≥ 30 mm, and were therefore
discharged, as their risk of delivery within 7 days
was< 2%11. Some tocolytics have been shown in some
RCTs and meta-analyses13 to be associated with signif-
icant decreases in PTB at different cut-offs. It is unknown
but possible that these tocolytics may be shown to be more
effective in prevention of PTB in women with not only
preterm contractions, but also short TVS CL, i.e. women
truly at high risk for PTB. Moreover, TVS CL assessment
may also be associated with a reduction in PTB by
reducing the need for serial digital vaginal examinations.
Indeed, serial digital examination has been associated
in several studies with an increased risk for PTB14,15,
possibly because these examinations have also been
associated with introduction of vaginal organisms into
the cervical canal16.
Given that we found a significant 36% reduction in the
primary outcome, but other outcomes, including clinically
challenging outcomes, were mostly statistically similar,
further study needs to be undertaken to understand better
whether and under what circumstances the predictive
characteristics of TVS CL screening can be translated
into better clinical management, and therefore better
outcomes. Future studies should report on all pertinent
maternal and perinatal outcomes, and include analyses on
cost-effectiveness. Most importantly, future studies should
include a clear protocol (e.g. tocolysis or no tocolysis) for
management of women based on TVS CL results, so that
it can be evaluated and replicated easily.
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Cribado mediante la longitud cervical para la prevenci o´n del parto pret e´rmino en embarazos con
feto u´nico y riesgo de parto prematuro: revis i o´n sistema´t ica y metaana´l is is de ensayos controlados
aleatorizados haciendo uso de los datos individuales de las pacientes
RESUMEN
Objetivo El cribado mediante la longitud cervical obtenida con ecografı´a transvaginal (ETV) ha demostrado ser una
buena prueba para la prediccio´n del parto prete´rmino esponta´neo (PPTE) en embarazos con feto u´nico sintoma´ticos
debido a la amenaza de parto prete´rmino (PPT). El objetivo de esta revisio´n y metaana´lisis de los datos de participantes
individuales fue evaluar el efecto de medir la longitud cervical (LC) mediante ETV con el fin de prevenir el parto
prematuro en embarazos u´nicos con amenaza de PPT.
Me´todos Se realizaron bu´squedas en los ficheros de ensayos de Cochrane Pregnancy and Childbirth Group y
Complementary Medicine Field (mayo de 2016), y en las listas de referencias de los estudios encontrados. Los
criterios de seleccio´n incluyeron ensayos controlados aleatorizados de embarazos con feto u´nico y riesgo de PPT con
aleatorizacio´n de la paciente basada principalmente en el cribado mediante la LC (grupo de intervencio´n), el cribado
mediante la LC sin conocimiento de los resultados, o sin cribado de LC (grupo de control). Las participantes fueron
mujeres embarazadas con feto u´nico desde las 23 + 0 hasta las 36 + 6 semanas y con riesgo de PPT. Se establecio´
contacto con los autores de los ensayos incluidos para solicitar el acceso a los datos y llevar a cabo un metaana´lisis
de los datos de las participantes individualmente. Los datos proporcionados por los investigadores se agregaron a una
base de datos maestra creada especı´ficamente para esta revisio´n. El resultado primario fue el PPTE < 37 semanas. Las
medidas resumen se reportaron como riesgo relativo (RR) o como diferencia de medias (DM) con IC del 95%.
Resultados En el metaana´lisis se incluyeron tres ensayos con un total de 287 embarazos con feto u´nico y riesgo de PPT
entre 24 + 0 y 35 + 6 semanas, de los cuales 145 fueron asignados al azar a un cribado mediante la LC con conocimiento
de los resultados y 142 a aquellos para los que se desconocı´a la LC. En comparacio´n con el grupo control, las mujeres
que fueron asignadas aleatoriamente al grupo en el que se conocı´a la LC tuvieron una tasa de parto prematuro a< 37
semanas significativamente menor (22,1% vs. 34,5%; RR 0,64 (IC 95%, 0,44–0,94); 3 ensayos; 287 participantes ) y
una edad gestacional al momento del parto ma´s tardı´a (DM 0,64 (IC 95%, 0.03–1.25) semanas; DM 4,48 (IC 95%,
1,18–8,98) dı´as; 3 ensayos; 287 participantes). El resto de los resultados para los cuales habı´a datos disponibles fueron
similares en ambos grupos.
Conclusiones Existe una asociacio´n significativa entre el conocimiento de la LC obtenida mediante ETV y una menor
incidencia de PPTE y edad gestacional ma´s tardı´a en el momento del parto en embarazos con feto u´nico sintoma´ticos
debido al riesgo de parto prete´rmino (PPT). Teniendo en cuenta que en el metaana´lisis se encontro´ una reduccio´n
significativa del 36% en el resultado primario, pero que los otros resultados fueron estadı´sticamente similares en su
mayorı´a, sera´n necesarios ma´s estudios para entender mejor si las propiedades predictivas del cribado mediante la LC
obtenida con ETV se pueden traducir en una mejor atencio´n clı´nica y por lo tanto mejores resultados dependiendo de
las circunstancias.
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